Vector Labs Ab02937-10.0 Anti-PCSK9 [3D2], Human IgG1, kappa (200 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: 3D2
Synonyms: NARC1; NARC-1; PC9; Proprotein convertase subtilisin/kexin type; Neural apoptosis-regulated convertase 1; Proprotein convertase 9; Subtilisin/kexin-like protease PC9
Amount: 200 μg
Application Codes Clone: ELISA; BLI; block; inhibit; functional assay; therapeutic
Shipping Temperature: Wet Ice
Origin Pub PMID: 33416098
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG1
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity Statement: This antibody binds PCSK9 and blocks the PCSK9-LDLR interaction in a dose-dependent manner with an IC50 of 2.25±1.23 nM (PMID: 33416098). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease enzyme encoded by the PCSK9 gene in humans and it plays a role in regulation of circulating cholesterol. It is associated with autosomal dominant hypercholesterolemia, a state of elevated levels of LDL (low-density lipoprotein) cholesterol. Autosomal dominant hypercholesterolemia can result in severe implications such as stroke and coronary heart disease.
Application Notes: Indirect binding ELISA were performed to assess the specificity of this antibody against PCSK9. Biolayer interferometry analysis suggested that IgG1 version of this antibody had a binding affinity of 1.96±1.56X10−10 M towards PCSK9. In vitro, the PCSK9/low-density lipoprotein receptor (LDLR) pathway of Hep-G2 cells was inhibited by 3D2 treatment, thereby increasing LDL uptake in these cells. In addition, combination treatment with 3D2 and statin was more effective at increasing LDLR levels than treatment with 3D2 or statin alone. Furthermore, in mice treatment with this antibody resulted in a 3-fold increase in hepatic LDLR levels, and lowered total serum cholesterol by up to 61.5% in vivo (PMID: 33416098).

Product Class:	Purified
Clone ID:	3D2
Synonyms:	NARC1; NARC-1; PC9; Proprotein convertase subtilisin/kexin type; Neural apoptosis-regulated convertase 1; Proprotein convertase 9; Subtilisin/kexin-like protease PC9
Amount:	200 μg
Application Codes Clone:	ELISA; BLI; block; inhibit; functional assay; therapeutic
Shipping Temperature:	Wet Ice
Origin Pub PMID:	33416098
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG1
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity Statement:	This antibody binds PCSK9 and blocks the PCSK9-LDLR interaction in a dose-dependent manner with an IC50 of 2.25±1.23 nM (PMID: 33416098). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease enzyme encoded by the PCSK9 gene in humans and it plays a role in regulation of circulating cholesterol. It is associated with autosomal dominant hypercholesterolemia, a state of elevated levels of LDL (low-density lipoprotein) cholesterol. Autosomal dominant hypercholesterolemia can result in severe implications such as stroke and coronary heart disease.
Application Notes:	Indirect binding ELISA were performed to assess the specificity of this antibody against PCSK9. Biolayer interferometry analysis suggested that IgG1 version of this antibody had a binding affinity of 1.96±1.56X10−10 M towards PCSK9. In vitro, the PCSK9/low-density lipoprotein receptor (LDLR) pathway of Hep-G2 cells was inhibited by 3D2 treatment, thereby increasing LDL uptake in these cells. In addition, combination treatment with 3D2 and statin was more effective at increasing LDLR levels than treatment with 3D2 or statin alone. Furthermore, in mice treatment with this antibody resulted in a 3-fold increase in hepatic LDLR levels, and lowered total serum cholesterol by up to 61.5% in vivo (PMID: 33416098).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews